2023
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis
Blauvelt A, Rich P, Sofen H, Strober B, Merola J, Lebwohl M, Morita A, Szepietowski J, Lambert J, Hippeli L, Colston E, Balagula E, Banerjee S, Thaçi D. Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis. Journal Of The American Academy Of Dermatology 2023, 90: 775-782. PMID: 38122848, DOI: 10.1016/j.jaad.2023.11.060.Peer-Reviewed Original ResearchPsoriasis Scalp Severity IndexSevere scalp psoriasisScalp psoriasisPlaque psoriasisSeverity IndexWeek 16Physician's Global Assessment 0/1Physician Global Assessment scoreGlobal phase 3Double-blinded trialEntire study populationGlobal assessment scorePhase 3Pooled secondary analysisOral placeboScalp involvementSevere psoriasisAdverse eventsSubset analysisStudy populationPsoriasisDeucravacitinibResponse rateSecondary analysisPlaceboOrismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)
Warren R, French L, Blauvelt A, Langley R, Egeberg A, Mrowietz U, Hunter H, Gooderham M, Soerensen P, Andres P, Sommer M, Carlsson A, Kjøller K, Strober B. Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS). Journal Of The American Academy Of Dermatology 2023, 90: 494-503. PMID: 37951245, DOI: 10.1016/j.jaad.2023.11.005.Peer-Reviewed Original ResearchSevere psoriasisWeek 16PDE4 inhibitionPhase 2b trialSevere plaque psoriasisDose-ranging studyModified-release formulationTolerability effectsPlaque psoriasisBaseline characteristicsEfficacy endpointPrimary endpointPsoriasis AreaSafety findingsSafety profileStudy populationPhase 2bPotential treatmentPsoriasisDisease proportionsGreater efficacyPlaceboPercentage changeSmall sample sizeSeverity IndexReal-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry
Strober B, Ferris L, Callis Duffin K, Janak J, Sima A, Eckmann T, Patel M, Photowala H, Garg V, Armstrong A. Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2023, 90: 82-90. PMID: 37739267, DOI: 10.1016/j.jaad.2023.08.097.Peer-Reviewed Original ResearchDermatology Life Quality Index scoresLife Quality Index scoresPsoriasis RegistryQuality Index scoresSevere psoriasisPsoriasis symptomsClear skinIndex scoreReal-world treatment effectivenessPrior biologic treatmentSevere plaque psoriasisInflammatory skin diseasePatient-reported outcomesEntire study populationReal-world effectivenessSignificant reductionPlaque psoriasisEligible adultsPatient adherenceBiologic treatmentActivity impairmentObservational studyStudy populationRisankizumabPsoriasis
2021
POS1032 EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
Mease P, Lertratanakul A, Strober B, Tsuji S, Richette P, Lovan C, Feng D, Anderson J, Van den Bosch F. POS1032 EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS. Annals Of The Rheumatic Diseases 2021, 80: 788-789. DOI: 10.1136/annrheumdis-2021-eular.564.Peer-Reviewed Original ResearchMinimal disease activityBiologic DMARDsOverall study populationInadequate responseAbbVie Inc.Boehringer IngelheimSpeakers bureauClinical trialsStudy populationEli LillyConsistent efficacyBristol-MyersFirst-line anti-TNF therapyDisease-modifying anti-rheumatic drugsSF-36 physical component summaryAnti-TNF therapyComprehensive disease controlPrior inadequate responseSubgroups of ptsThird-line therapyAnti-rheumatic drugsInvestigator's Global AssessmentSanofi-AventisPhysical component summaryConfidence intervals
2017
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal Of The American Academy Of Dermatology 2017, 78: 70-80. PMID: 29102053, DOI: 10.1016/j.jaad.2017.08.051.Peer-Reviewed Original ResearchConceptsImpact of treatmentPsoriasis Longitudinal AssessmentConventional therapyAdverse eventsDepressive symptomsIncidence rateLongitudinal assessmentConventional systemic therapiesSevere psoriasisBiologic therapySystemic therapyLower incidenceStudy populationPatientsTherapySymptomsPsoriasisRegistryBiologicsPhototherapyDepressionIncidenceMultivariate modelingRiskTreatment